Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2011

Xarelto(Rivaroxaban)Johnson & Johnson logoJNJ

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Johnson & Johnson

$6.23B

Medicare cost, 2024

Medicare drug plans spent $6.2 billion on Xarelto (rivaroxaban) in 2024, for 6.7 million prescriptions and refills filled by 1.3 million patients. It ranks 5th among all drugs by Medicare drug plan spending. California accounts for the most spending ($495.2 million, 8% of the total). It is made by Johnson & Johnson (JNJ).

Medicare cost, 2024

$6.23B

-1.2% from 2023

Prescriptions

6.7M

$935.73 per claim

Patients

1.3M

348,034 prescribers

Total spending, 2024

$6.23B

$4,717.75 per patient

Questions and answers

How much does Medicare spend on Xarelto?

Medicare prescription drug plans paid $6.23B for Xarelto in 2024, for 6,658,485 prescriptions and refills to 1,320,644 patients (down 1.2% from 2023). The average cost per claim was $935.73.

Which state spends the most on Xarelto?

California had the highest Medicare cost for Xarelto in 2024: $495.2M for 511,553 claims, followed by Florida ($475.3M).

Who prescribes Xarelto the most?

Cindy S Kennedy, pharmacist in Charlotte, NC, had the highest Medicare cost for Xarelto in 2024: 1,585 claims costing $2.5M.

Who makes Xarelto?

Xarelto is made by Johnson & Johnson (JNJ), listed in the Medicare spending data as Janssen Pharm..

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Xarelto was $6.23B in 2024, after a high of $6.31B in 2023.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Xarelto, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Cindy S Kennedy Charlotte, NCPharmacist1,585473$2.5M
Huong K Ha Sepulveda, CAPharmacist1,856660$2.4M
Prakash D Shah Milwaukee, WICardiology1,950478$2.4M
Jennifer L Tresser Martinez, CAPharmacist1,680633$2.3M
Mayer Rashtian Pasadena, CAClinical Cardiac Electrophysiology1,800462$2.1M
David H Lau New York, NYCardiology2,571419$2.0M
Carmen Wong Union City, CAPharmacist1,387496$1.7M
Jordan Wong San Francisco, CAPharmacist1,318449$1.7M
Yili Huang Elmhurst, NYCardiology1,603405$1.5M
Cres P Miranda Jr. Las Vegas, NVCardiology1,138343$1.4M
Hyeon Hye Lee Cupertino, CAPharmacist992370$1.3M
William H Skinner Lexington, KYCardiology1,173269$1.3M
Ajay Tuli Tucson, AZInterventional Cardiology975268$1.3M
Michael C Liou New York, NYInterventional Cardiology1,537269$1.3M
David H Hoch Roslyn, NYClinical Cardiac Electrophysiology969304$1.2M
Cash Casey Elmhurst, ILClinical Cardiac Electrophysiology1,032240$1.2M
Hossein Amirani Wichita, KSCardiology1,261248$1.2M
Harry R Hawthorne Alexandria, LAClinical Cardiac Electrophysiology1,472288$1.2M
Maria R Peluso Winston Salem, NCPharmacist754262$1.2M
Lynne Hung Mission Viejo, CAClinical Cardiac Electrophysiology1,119285$1.2M
Avichai Eres Lexington, KYCardiology968254$1.2M
Mauricio Melhado West Palm Beach, FLCardiology1,473305$1.2M
Dharmesh S Patel Southaven, MSCardiology1,243319$1.2M
Paul E Bejarano Tucson, AZCardiology822229$1.1M
Ronald G Ryder Hamilton, NJCardiology908226$1.1M

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022339,9186,523,3661,311,050$5.77B
2023343,4376,651,3631,323,475$6.31B
2024348,0346,658,4851,320,644$6.23B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Janssen Pharm.JNJ logoJNJ6,660,246$6.23B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
28
RxNorm concept IDs
1114198, 1114202, 1232082, 1232084, 1232086
Application numbers
NDA022406, NDA215859

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube